However, it should be noted that Mendelian randomization analyses have not supported a causal role of secreted Lp-PLA2 in coronary heart disease (40), and phase III trials of darapladib, an Lp-PLA2 inhibitor, have shown no benefit in patients with stable coronary heart disease (41) or acute coronary syndromes (42) when added to conventional treatments including statins. Here, PLA2G7 is linked to coronary artery disorder.